-
EP3529236
European procedure
Extract from the Register of European Patents
EP About this file: EP3529236
| EP3529236 - CRYSTALLINE FORMS OF ERAVACYCLINE [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 05.01.2024 Database last updated on 28.05.2024 | |
| Former | Grant of patent is intended Status updated on 31.05.2023 | ||
| Former | Examination is in progress Status updated on 18.02.2022 | ||
| Former | Request for examination was made Status updated on 26.07.2019 | ||
| Former | The international publication has been made Status updated on 28.04.2018 | ||
| Former | unknown Status updated on 16.11.2017 | Most recent event Tooltip | 05.01.2024 | (Expected) grant | published on 07.02.2024 [2024/06] | Applicant(s) | For all designated states Tetraphase Pharmaceuticals, Inc. 35 Gatehouse Drive, Suite E0 Waltham, MA 02451 / US | [2024/02] |
| Former [2023/45] | For all designated states Tetraphase Pharmaceuticals, Inc. 201 Jones Road, Suite 400 Waltham, MA 02451-1637 / US | ||
| Former [2019/35] | For all designated states Tetraphase Pharmaceuticals, Inc. 480 Arsenal Street, Suite 110 Watertown, MA 02472 / US | Inventor(s) | 01 /
LAFRANCE, Danny 22A Wellesley Ave Natick, MA 01760 / US | 02 /
HOGAN, Philip, C. 437 Washington St. Apt. 1 Brighton, MA 02135 / US | 03 /
LIU, Yansheng 8 Ginn Road Winchester, MA 01890 / US | 04 /
HE, Minsheng 34 Marland Street Andover, MA 01810 / US | 05 /
CHEN, Chi-Li 11 Waban Street Newton, MA 02458 / US | 06 /
NIU, John 20 Reeves Road Bedford, MA 01730 / US | [2019/35] | Representative(s) | Snodin, Michael D. Park Grove IP MediCity Nottingham D6 Building, Thane Road Nottingham NG90 6BH / GB | [2024/06] |
| Former [2019/35] | Snodin, Michael D. Park Grove IP BioCity Nottingham Pennyfoot Street Nottingham NG1 1GF / GB | Application number, filing date | 17794505.2 | 19.10.2017 | [2019/35] | WO2017US57385 | Priority number, date | US201662410230P | 19.10.2016 Original published format: US 201662410230 P | [2019/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018075767 | Date: | 26.04.2018 | Language: | EN | [2018/17] | Type: | A1 Application with search report | No.: | EP3529236 | Date: | 28.08.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.04.2018 takes the place of the publication of the European patent application. | [2019/35] | Type: | B1 Patent specification | No.: | EP3529236 | Date: | 07.02.2024 | Language: | EN | [2024/06] | Search report(s) | International search report - published on: | EP | 26.04.2018 | Classification | IPC: | C07D295/15, A61P1/00, A61P35/00, A61P31/00, A61K31/65, A61P1/02, A61P31/04, A61P43/00, A61P13/02 | [2023/25] | CPC: |
C07D295/15 (EP,KR,US);
A61K31/65 (KR);
A61P1/00 (EP,KR);
A61P1/02 (EP);
A61P13/02 (EP);
A61P31/00 (EP);
A61P31/04 (EP,KR,US);
A61P35/00 (EP,KR);
A61P43/00 (EP);
|
| Former IPC [2019/35] | C07D295/15, A61K31/65, A61P31/00, A61P35/00, A61P1/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/35] | Extension states | BA | 01.05.2019 | ME | 01.05.2019 | Validation states | MA | 01.05.2019 | MD | 01.05.2019 | Title | German: | KRISTALLINE FORMEN VON ERAVACYCLIN | [2019/35] | English: | CRYSTALLINE FORMS OF ERAVACYCLINE | [2019/35] | French: | FORMES CRISTALLINES DE L'ÉRAVACYCLINE | [2019/35] | Entry into regional phase | 01.05.2019 | National basic fee paid | 01.05.2019 | Designation fee(s) paid | 01.05.2019 | Examination fee paid | Examination procedure | 01.05.2019 | Examination requested [2019/35] | 01.05.2019 | Date on which the examining division has become responsible | 28.11.2019 | Amendment by applicant (claims and/or description) | 21.02.2022 | Despatch of a communication from the examining division (Time limit: M06) | 18.08.2022 | Reply to a communication from the examining division | 01.06.2023 | Communication of intention to grant the patent | 11.10.2023 | Fee for grant paid | 11.10.2023 | Fee for publishing/printing paid | 11.10.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 01.05.2019 | Renewal fee patent year 03 | 27.01.2021 | Renewal fee patent year 04 | 27.01.2022 | Renewal fee patent year 05 | 27.12.2022 | Renewal fee patent year 06 | 27.12.2023 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 31.10.2020 | 04 M06 Fee paid on 27.01.2021 | 31.10.2021 | 05 M06 Fee paid on 27.01.2022 | 31.10.2022 | 06 M06 Fee paid on 27.12.2022 | 31.10.2023 | 07 M06 Fee paid on 27.12.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2016065290 (TETRAPHASE PHARMACEUTICALS INC [US]) [I] 1-52 * page 56 - page 58; example 3 * * page 1, paragraph 2 *; | [XP]WO2017125557 (SANDOZ AG [CH]) [XP] 1-52* the whole document *; | [I] - MAGNUS RONN ET AL, "Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, US, (20130517), vol. 17, no. 5, doi:10.1021/op4000219, ISSN 1083-6160, pages 838 - 845, XP055254495 [I] 1-52 * page 838, column 2, paragraph 2 * * page 842, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1021/op4000219 | [A] - CAIRA ED - MONTCHAMP JEAN-LUC, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, (19980101), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [A] 1-52 * the whole document * DOI: http://dx.doi.org/10.1007/3-540-69178-2_5 | by applicant | US3304227 | US4666897 | US4704383 | US4925833 | US4935412 | US5231017 | US5258371 | US5308839 | US5321017 | USRE34656E | US5459135 | US5523297 | US5532227 | US5668122 | US5770588 | US5773430 | US5789395 | US5827840 | US5834450 | US5834449 | US5837696 | US5843925 | US5919774 | US5919775 | US5929055 | US5977091 | US5998390 | US6015804 | US6043231 | US6043225 | US6100248 | US6231894 | US6277061 | US8796245 | US8906887 | - VAN DER BOZERT et al., Cancer Res., (19880000), vol. 48, pages 6686 - 6690 | - S. E. DOWD et al., PloS one, (20080000), vol. 3, page e3326 | - H. WISPLINGHOFF et al., Clin. Infect. Dis., (20040000), vol. 39, pages 311 - 317 | - LIEDTKE et al., Ann. Neurol., (19980000), vol. 44, pages 35 - 46 | - CHANDLER et al., J. Neuroimmunol., (19970000), vol. 72, pages 155 - 71 | - STETLER-STEVENSON et al., Annu. Rev. Cell Biol., (19930000), vol. 9, pages 541 - 73 | - TRYGGVASON et al., Biochim. Biophys. Acta, (19870000), vol. 907, pages 191 - 217 | - LI et al., Mol. Carcillog., (19980000), vol. 22, pages 84 - 89 | - GREENWALD et al., Bone, (19980000), vol. 22, pages 33 - 38 | - RYAN et al., Curr. Op. Rheumatol., (19960000), vol. 8, pages 238 - 247 | - Phys. Rev., (19970000), vol. A56, no. 6, pages 4554 - 4568 |